January 12, 2011 — Researchers at MIT and Brigham and Women’s Hospital have shown that they can deliver the cancer drug cisplatin much more effectively and safely in a form that has been encapsulated in a nanoparticle, targeted to prostate tumor cells and activated once it reaches its target.
Using the new particles, the researchers were able to successfully shrink tumors in mice, using only one-third the amount of conventional cisplatin needed to achieve the same effect. That could help reduce cisplatin’s potentially severe side effects, which include kidney damage and nerve damage.
In 2008, the researchers showed that the nanoparticles worked in cancer cells grown in a lab dish. Now that the particles have shown promise in animals, the team hopes to move on to human tests.
"At each stage, it’s possible there will be new roadblocks that will come up," noted Stephen Lippard, the Arthur Amos Noyes Professor of Chemistry and a senior author of the paper, which appears in the Proceedings of the National Academy of Sciences the week of Jan. 10. Additional animal testing is needed before the cisplatin-carrying particles can go into human clinical trials, says Farokhzad. "At the end of the day, if the development results are all promising, then we would hope to put something like this in humans within the next three years," he says.
Omid Farokhzad, associate professor at Harvard Medical School and director of the Laboratory of Nanomedicine and Biomaterials at Brigham and Women’s Hospital, is also a senior author of the paper. Shanta Dhar, a postdoctoral associate in Lippard’s lab, and Nagesh Kolishetti, a postdoctoral associate in Farokhzad’s lab, are co-lead authors.
Cisplatin, which doctors began using to treat cancer in the late 1970s, destroys cancer cells by cross-linking their DNA, which ultimately triggers cell death. Despite its adverse side effects, which also include nerve damage and nausea, about half of all cancer patients receiving chemotherapy are taking platinum drugs. Read about other MIT research on cisplatin.
Conventional cisplatin has a relatively short lifetime in the bloodstream. Only about 1% of the dose given to a patient ever reaches the tumor cells’ DNA, and about half of it is excreted within an hour of treatment.
To prolong the time in circulation, the researchers decided to encase a derivative of cisplatin in a hydrophobic nanoparticle. First, they modified the drug, which is normally hydrophilic, with two hexanoic acid units. That enabled them to encapsulate the resulting prodrug — a form that is inactive until it enters a target cell — in a nanoparticle. To help the nanoparticles reach their target, the researchers also coated them with molecules that bind to PSMA (prostate specific membrane antigen), a protein found on most prostate cancer cells.
Using this approach, much more of the drug reaches the tumor. The researchers found that the nanoparticles circulated in the bloodstream for about 24 hours, at least 5 times longer than un-encapsulated cisplatin. They also found that it did not accumulate as much in the kidneys as conventional cisplatin.
After showing the nanoparticles’ improved durability in the blood, the researchers tested their effectiveness by treating mice implanted with human prostate tumors. They found that the nanoparticles reduced tumor size as much as conventional cisplatin over 30 days, but with only 30% of the dose.
This type of nanoparticle design could be easily adapted to carry other types of drugs, or even more than one drug at a time, as the researchers reported in a PNAS paper last October. It could also be designed to target tumors other than prostate cancer, as long as those tumors have known receptors that could be targeted. One example is the Her-2 receptor abundant in some types of breast cancer, says Lippard. Read about breast cancer research involving MEMS.
The particles tested in this paper are based on the same design as particles developed by Farokhzad and MIT Institute Professor Robert Langer that deliver the cancer drug docetaxel. A Phase I clinical trial to assess those particles began last week, run by BIND Biosciences.
Source: "Targeted delivery of cisplatin prodrug for safer and more effective prostate cancer therapy in vivo," by Shanta Dhar, Nagesh Kolishetti, Stephen J. Lippard, and Omid C. Farokhzad. Proceedings of the National Academy of Sciences, 10, January 2011.
Funding: National Cancer Institute, National Institute of Biomedical Imaging and Bioengineering Grant, Koch-Prostate Cancer Foundation Award in Nanotherapeutics.
Courtesy of Anne Trafton, MIT News Office, www.mit.edu
Follow Small Times on Twitter.com by clicking www.twitter.com/smalltimes. Or join our Facebook group